RCS - Creo Medical Group - UK private hospital use Speedboat for cancer case

Creo MedicalAnnouncement

29/04/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260429:nRSc2915Ca&default-theme=true

RNS Number : 2915C  Creo Medical Group PLC  29 April 2026

 

Creo Medical Group plc

("Creo", the "Company" or the "Group")

 

First UK private hospital use Speedboat for colorectal cancer case

 

Creo Medical Group plc (AIM: CREO), the medical device company focused on the
emerging field of minimally invasive surgical endoscopy for pre-cancer and
cancer patients, notes the announcement from The London Clinic, one of the
UK's leading private hospitals, which confirms that it has successfully
launched the Speedboat procedure for early colorectal cancer.

 

The announcement is available here
https://www.thelondonclinic.co.uk/news-articles/london-clinic-performs-first-ever-speedboat-submucosal-dissection-for-early-colorectal-cancer
(https://www.thelondonclinic.co.uk/news-articles/london-clinic-performs-first-ever-speedboat-submucosal-dissection-for-early-colorectal-cancer)
and is reproduced below in full:

 

The London Clinic Performs First-Ever Speedboat Submucosal Dissection for
Early Colorectal Cancer

 

The London Clinic is proud to announce a significant milestone in advanced
endoscopic care: Dr Roser Vega
(https://www.thelondonclinic.co.uk/experts/dr-roser-vega) has successfully
performed the hospital's first-ever Speedboat submucosal dissection (SSD),
offering a highly innovative, organ-sparing treatment for patients with early
colorectal cancer
(https://www.thelondonclinic.co.uk/services/conditions/colorectal-cancer) .

 

This achievement marks The London Clinic as the first private hospital in the
UK to introduce and deliver this cutting-edge technique, reinforcing its
commitment to pioneering minimally invasive treatments and improving patient
outcomes.

 

Speedboat submucosal dissection (SSD) is a form of endoscopic submucosal
dissection (ESD) performed using the Speedboat® device, an advanced surgical
instrument that combines cutting, coagulation, and dissection capabilities in
a single tool. The device uses innovative technology developed and
manufactured by Creo Medical, enabling clinicians to perform highly precise
and controlled removal of early-stage cancerous and pre-cancerous lesions from
the gastrointestinal tract.

 

Unlike traditional surgical approaches, which may require partial removal of
the colon, SSD offers a less invasive, organ-preserving alternative. Patients
benefit from reduced recovery times, fewer complications, and the potential to
avoid major surgery altogether.

 

Dr Roser Vega, Consultant Gastroenterologist at The London Clinic, commented:

"We are delighted to bring this advanced technique to patients in the private
sector. Speedboat submucosal dissection represents a major step forward in the
treatment of early colorectal cancer, allowing us to remove lesions
effectively while preserving organ function. This approach significantly
improves patient experience and outcomes."

 

The introduction of SSD at The London Clinic reflects the hospital's ongoing
investment in innovative technologies and specialist expertise. By offering
this service, The London Clinic is expanding access to state-of-the-art,
minimally invasive cancer
(https://www.thelondonclinic.co.uk/specialities/cancer-care) treatments within
the UK's private healthcare sector.

 

This milestone further strengthens The London Clinic's position as a leader in
advanced endoscopy and patient-centred care.

 

The introduction of Speedboat submucosal dissection at The London Clinic
reflects continued investment by leading institutions in advanced endoscopic
techniques and reinforces Creo Medical's position at the forefront of
minimally invasive cancer care. The procedure further expands access to
state‑of‑the‑art endoscopic procedures within the UK, supporting broader
adoption across both public and private healthcare systems.

 

This milestone builds on the growing clinical momentum for Speedboat across
key geographies and high‑value procedural areas, including complex upper and
lower gastrointestinal interventions, and further validates the scalability
and relevance of Creo's Advanced Energy platform.

 

 

Craig Gulliford, Chief Executive Officer of Creo Medical, commented:

"The successful launch of the Speedboat service at The London Clinic is a
significant endorsement of our technology and its role in delivering
organ‑sparing, minimally invasive cancer treatments in a private healthcare
setting here in the UK. Adoption by a leading private hospital highlights the
growing clinical confidence in Speedboat, reinforcing our belief that advanced
endoscopic products like ours will play an increasingly important role in
improving both the clinical outcomes for patients and the accessibility of
these procedures. We are delighted to see Speedboat continuing to expand its
footprint across centres of excellence and delivering meaningful benefits for
both clinicians and patients."

 

For further information please contact:

 

 Creo Medical Group plc                                                         www.creomedical.com
                                                                                (https://protect.checkpoint.com/v2/___http:/www.creomedical.com/___.YzJ1OmludHVpdGl2ZTpjOm86NWJlYzBmMzJjY2MyZTBiZWFkNmJkZmVmNzdhM2MwMTI6NjoyYWU4OjczNzQyNWUwODBjYTEwNzAxYWMzNWEyZDQ3YzI1ZmEwYWMzYTc4M2Q2M2NjYzEyNTQwZWM3ODc4NTk3NTE4YTQ6cDpUOk4)
 Richard Craven, Company Secretary                                              Via Walbrook PR

 Deutsche Numis (Nominated Adviser, Joint Broker and Financial Adviser)         +44 (0)20 7260 1000

 Duncan Monteith / Sher Shah

 Shore Capital (Joint Broker)                                                   +44 (0)20 7408 4090
 Daniel Bush / Lucy Bowden

 Walbrook PR Ltd                       Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com (mailto:creo@walbrookpr.com)
 Paul McManus / Alice Woodings         Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

 

About Creo Medical - www.creomedical.com (http://www.creomedical.com)

Creo is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation,
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions. CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less invasive and
more cost-efficient option for procedures.

 

About The London Clinic - www.thelondonclinic.co.uk
(http://www.thelondonclinic.co.uk)

The London Clinic is one of the UK's leading private hospitals, delivering
world-class care across a range of specialties. With a focus on innovation,
clinical excellence, and patient wellbeing, the hospital continues to pioneer
advanced treatments and technologies to improve healthcare outcomes.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAKZGZDNRNGVZM



            Copyright 2019 Regulatory News Service, all rights reserved